Business Wire

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly

22.5.2026 13:45:00 CEST | Business Wire | Press release

Share

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/

Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve.

Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the same time, access to prevention remains unequal, with underserved communities often facing the greatest barriers to early screening and timely care, as well as reliable health information. The Future Health Challenge focused on solutions designed to detect health risks sooner, monitor population-level data, and support faster decision-making by health authorities.

Five finalist teams presented their solutions to an international audience spanning global health, philanthropy, investment, technology and life sciences, with the judging team awarding prizes to the following teams:

  • ThinkMD, Australia
    USD 200,000, Winner
    ThinkMD equips frontline health workers with mobile clinical decision-support tools that improve triage, treatment, and referral, while turning routine care encounters into real-time population health signals. The platform is already used by more than 9,000 frontline workers across 885 facilities, with the platform’s ability to act as an early warning system demonstrated through previously detected symptom patterns preceding a cholera outbreak in Zambia.

  • Vector Control Innovations, United States
    USD 50,000, Distinguished Finalist
    VectorCam uses AI-enabled mosquito surveillance to detect changing vector risks earlier, helping health systems target interventions before outbreaks escalate. Field evaluations of VectorCam’s impact have shown clear improvements in both efficiency and data quality, with evaluations showing data completeness increasing from around 60% to over 90%.

  • Huna, Brazil
    USD 50,000, Distinguished Finalist
    Huna applies AI to routine blood test data to identify people at elevated cancer risk earlier and guide them into appropriate screening and care pathways. In Brazil, its pilots have screened more than 500,000 patients, and across all deployments to date, hundreds of cancer cases have been detected, many of which would likely have been found later when treatment is more complex and expensive.

Delivered in collaboration with MIT Solve, the Future Health Challenge is part of Future Health’s year-round programme of activities designed to identify and champion high-potential talent globally, connecting innovators with funding, partnerships and pathways to scale solutions that advance longer, healthier lives.

Dr. Jackie Rabec, Co-Founder of ThinkMD, said: “We are thrilled to be the recipients of this award, and we are excited to be able to use it to scale our impact. Our next stage of growth will be expanding in priority markets across Nigeria, Rwanda, Uganda and Somalia, validating our next generation multimodal conversational interface and furthering our self-care product to deliver health intelligence into the hands of citizens.”

Dr. Asma Al Mannaei, Executive Director of the Health and Life Sciences Sector at the Department of Health – Abu Dhabi said “Too often, health systems only detect risk once it has become illness, when treatment is more complex and outcomes are worse. Solutions from the Future Health Challenge are designed to identify risk earlier and support more timely decisions at a population level. The priority now is testing and scaling what works in real-world settings.”

Hala Hanna, Executive Director of MIT Solve, said: “The solutions emerging from this Challenge reflect both the urgency and the opportunity facing health systems globally. By bringing innovators together with policymakers, funders and implementers through platforms such as Future Health, we can help accelerate solutions that are locally grounded and capable of delivering impact at scale.”

MIT Solve has more than a decade of experience in delivering global innovation challenges across health, climate, learning and economic prosperity. To date, MIT Solve has mobilised over USD 80 million in funding for innovators worldwide, with supported solutions reaching more than 370 million lives.

The Challenge forms part of Future Health’s purpose to identify and support innovations that improve health outcomes. Beyond prize funding, participating teams will be connected to partners, investors and health authorities to support the next phase of development and adoption.

Representatives from finalist, semi-finalist and selected Honourable Mention teams will also be invited to showcase their innovations at the Abu Dhabi Future Health Summit, taking place from 20 to 22 October 2026.

Future Health continues to advance a year-round programme across longevity and precision medicine, intelligent health and AI, health system resilience and sustainability, and investment in life sciences, to empower better health worldwide. The platform will continue to introduce new opportunities for global collaboration and discovery of impactful solutions throughout the year.

For more information about the Future Health Challenge and upcoming programme milestones, visit www.futurehealthinitiative.ae

View source version on businesswire.com: https://www.businesswire.com/news/home/20260522587414/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye